157 related articles for article (PubMed ID: 37975277)
1. Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study.
Sano T; Amano K; Ide T; Isoda H; Honma Y; Morita Y; Yano Y; Nakamura H; Itano S; Miyajima I; Shirachi M; Kuwahara R; Ohno M; Kawaguchi T; Tsutsumi T; Nakano D; Arinaga-Hino T; Kawaguchi M; Eguchi Y; Torimura T; Takahashi H; Harada M; Kawaguchi T;
Hepatol Res; 2024 Apr; 54(4):326-335. PubMed ID: 37975277
[TBL] [Abstract][Full Text] [Related]
2. Dynamic α-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy.
Wu CK; Chang KC; Hung CH; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hu TH
J Antimicrob Chemother; 2016 Jul; 71(7):1943-7. PubMed ID: 27073265
[TBL] [Abstract][Full Text] [Related]
3. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study.
Ji D; Chen GF; Niu XX; Zhang M; Wang C; Shao Q; Wu V; Wang Y; Cheng G; Hurwitz SJ; Schinazi RF; Lau G
Metabol Open; 2021 Jun; 10():100090. PubMed ID: 33889834
[TBL] [Abstract][Full Text] [Related]
5. High Post-treatment α-Fetoprotein Levels and Aspartate Aminotransferase-to-Platelet Ratio Index Predict Hepatocellular Carcinoma in Hepatitis C Virus Decompensated Cirrhotic Patients with Sustained Virological Response After Antiviral Therapy.
Ji F; Zhou R; Wang W; Bai D; He C; Cai Z; Shen Y; Wang S; Deng H; Li Z
J Interferon Cytokine Res; 2017 Aug; 37(8):362-368. PubMed ID: 28731786
[TBL] [Abstract][Full Text] [Related]
6. Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis.
Masetti C; Lionetti R; Lupo M; Siciliano M; Giannelli V; Ponziani FR; Teti E; Dell'Unto C; Francioso S; Brega A; Montalbano M; Visco-Comandini U; Taibi C; Galati G; Vespasiani Gentilucci U; Picardi A; Andreoni M; Pompili M; Pellicelli AM; D'Offizi G; Gasbarrini A; De Santis A; Angelico M
J Viral Hepat; 2018 Dec; 25(12):1493-1500. PubMed ID: 30112854
[TBL] [Abstract][Full Text] [Related]
7. Metabolic dysfunction-associated steatotic liver disease increases hepatocellular carcinoma risk in chronic hepatitis B patients: a retrospective cohort study.
Lin M; Gao B; Peng M; Chen X; Xiao H; Shi M; Zhang X; Zeng F; Chi X
Front Physiol; 2024; 15():1347459. PubMed ID: 38405121
[No Abstract] [Full Text] [Related]
8. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication.
Lu MY; Yeh ML; Huang CI; Wang SC; Tsai YS; Tsai PC; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
World J Gastroenterol; 2022 Jan; 28(1):140-153. PubMed ID: 35125824
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
10. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K;
J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407
[TBL] [Abstract][Full Text] [Related]
11. Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis.
Tahata Y; Sakamori R; Yamada R; Kodama T; Hikita H; Nozaki Y; Oshita M; Hiramatsu N; Miyazaki M; Mita E; Yamamoto K; Ohkawa K; Kaneko A; Ito T; Doi Y; Yakushijin T; Hijioka T; Fukui H; Imanaka K; Yoshida Y; Yamada Y; Tatsumi T; Takehara T
Hepatol Res; 2022 Oct; 52(10):824-832. PubMed ID: 35749289
[TBL] [Abstract][Full Text] [Related]
12. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
13. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents.
Degasperi E; Perbellini R; D'Ambrosio R; Uceda Renteria SC; Ceriotti F; Perego A; Orsini C; Borghi M; Iavarone M; Bruccoleri M; Rimondi A; De Silvestri A; Sangiovanni A; Lampertico P
Aliment Pharmacol Ther; 2022 Feb; 55(3):350-359. PubMed ID: 34738664
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.
Fouad R; Elsharkawy A; Abdel Alem S; El Kassas M; Alboraie M; Sweedy A; Afify S; Abdellatif Z; Khairy M; Esmat G
Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1129-1134. PubMed ID: 30896550
[TBL] [Abstract][Full Text] [Related]
15. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents.
Huang CM; Hu TH; Chang KC; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hung CH; Cho CL; Wu CK
Medicine (Baltimore); 2017 Nov; 96(46):e8696. PubMed ID: 29145306
[TBL] [Abstract][Full Text] [Related]
16. Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.
Mawatari S; Kumagai K; Oda K; Tabu K; Ijuin S; Fujisaki K; Tashima S; Inada Y; Uto H; Saisyoji A; Hiramine Y; Hashiguchi M; Tamai T; Hori T; Taniyama O; Toyodome A; Sakae H; Kure T; Sakurai K; Moriuchi A; Kanmura S; Ido A
PLoS One; 2022; 17(1):e0262267. PubMed ID: 35020772
[TBL] [Abstract][Full Text] [Related]
17. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
[TBL] [Abstract][Full Text] [Related]
18. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.
Tateyama M; Yatsuhashi H; Taura N; Motoyoshi Y; Nagaoka S; Yanagi K; Abiru S; Yano K; Komori A; Migita K; Nakamura M; Nagahama H; Sasaki Y; Miyakawa Y; Ishibashi H
J Gastroenterol; 2011 Jan; 46(1):92-100. PubMed ID: 20711614
[TBL] [Abstract][Full Text] [Related]
19. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
Matsuura K; Sawai H; Ikeo K; Ogawa S; Iio E; Isogawa M; Shimada N; Komori A; Toyoda H; Kumada T; Namisaki T; Yoshiji H; Sakamoto N; Nakagawa M; Asahina Y; Kurosaki M; Izumi N; Enomoto N; Kusakabe A; Kajiwara E; Itoh Y; Ide T; Tamori A; Matsubara M; Kawada N; Shirabe K; Tomita E; Honda M; Kaneko S; Nishina S; Suetsugu A; Hiasa Y; Watanabe H; Genda T; Sakaida I; Nishiguchi S; Takaguchi K; Tanaka E; Sugihara J; Shimada M; Kondo Y; Kawai Y; Kojima K; Nagasaki M; Tokunaga K; Tanaka Y;
Gastroenterology; 2017 May; 152(6):1383-1394. PubMed ID: 28163062
[TBL] [Abstract][Full Text] [Related]
20. Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.
Myojin Y; Hikita H; Tahata Y; Doi A; Kato S; Sasaki Y; Shirai K; Sakane S; Yamada R; Kodama T; Hagiwara H; Imai Y; Hiramatsu N; Tamura S; Yamamoto K; Ohkawa K; Hijioka T; Fukui H; Doi Y; Yamada Y; Yakushijin T; Mita E; Sakamori R; Tatsumi T; Takehara T
Aliment Pharmacol Ther; 2022 Feb; 55(4):422-433. PubMed ID: 34812502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]